# Standard BioTools Inc. (LAB)

> Source: Nexqual · https://nexqual.com/LAB · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Standard BioTools Inc. (LAB), nexqual.com/LAB" · informational, not investment advice.

**Price:** USD 0.66 (+4.18% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 0.63 · day 0.63–0.67 · 52w 0.63–1.72 · market cap $258M · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $84.6M, net income $84.9M (100.4% margin), free cash flow -$82.6M (SEC filings).
- Valuation: P/E 3.0x.
- 1 of 80 tracked superinvestors hold LAB (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Analysts: Hold (mean 3.00 on a 1–5 scale) (1 analysts), mean target USD 1.35 (range 1.35–1.35).
- Total return with dividends: 1Y -48.8% vs S&P 500 +18.1%; 5Y -87.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-03, EPS estimate USD -0.02, revenue estimate $18.8M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $131M | $97.9M | $106M | $91.0M | $85.3M | $84.6M |
| Gross profit | — | $37.1M | $50.5M | $44.9M | $42.5M | — |
| Operating income | -$67.5M | -$116M | -$76.6M | -$127M | -$110M | -$95.5M |
| Net income | -$59.2M | -$190M | -$74.7M | -$139M | -$74.9M | $84.9M |
| EPS (diluted) | -$0.78 | -$2.43 | -$0.94 | -$0.52 | -$0.20 | — |
| Free cash flow | -$57.3M | -$93.2M | -$46.1M | -$152M | -$82.6M | -$82.6M |
| Gross margin | — | 37.8% | 47.4% | 49.3% | 49.9% | — |
| Operating margin | -51.7% | -118.6% | -72.0% | -140.1% | -129.2% | -112.8% |
| Net margin | -45.4% | -194.1% | -70.2% | -152.6% | -87.8% | 100.4% |
| Revenue growth | -5.5% | -25.0% | +8.6% | -14.4% | -6.2% | — |
| Cash + short-term investments | $29.5M | $167M | $115M | $293M | $188M | — |
| Total debt | — | $64.9M | $63.5M | $299K | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 3.0x · P/S 3.1x · P/B 0.5x · FCF yield -31.95% · Earnings yield 32.85%

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold LAB. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.14% | $48.3M | Unchanged |

## Analysts
Consensus Hold (mean 3.00 on a 1–5 scale), 1 analysts; mean target USD 1.35 (low 1.35, high 1.35).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -48.8% | -87.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -49.0% | -34.1% |
| Volatility (annualized) | 71.3% | 72.9% |
| Max drawdown | -62.5% (Dec 2025→Oct 2026) | -88.0% (Oct 2021→Aug 2026) |

## Peers (Medical Devices)
ESTA (Establishment Labs Holdings Inc) USD 61.36 +4.98% · ALMR (Alamar Biosciences, Inc.) USD 27.42 +16.58% · INSP (Inspire Medical Systems, Inc.) USD 70.12 +1.83% · BFLY (Butterfly Network, Inc.) USD 7.85 -3.09% · AXGN (AxoGen, Inc.) USD 35.63 -1.49% · UFPT (UFP Technologies, Inc.) USD 297.19 +0.99%

## More
Full page: https://nexqual.com/LAB · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt